Rebman, Alison W.
Yang, Ting
Wang, Lin
Marsteller, Jill A.
Murphy, Shannon M. E.
Uriyo, Maria
Aucott, John N.
Funding for this research was provided by:
Steven and Alexandra Cohen Foundation
Article History
Received: 24 April 2023
Accepted: 12 August 2023
First Online: 29 August 2023
Declarations
:
: This study was approved by the Johns Hopkins Medicine Institutional Review Board and the Johns Hopkins HealthCare Data Sharing Committee. The need for informed consent was waived by the Johns Hopkins Medicine Institutional Review Board as a retrospective analysis of existing, de-identified data that does not involve direct interaction with human subjects. All research was performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki.
: Not applicable.
: JNA received consulting fees from the Pfizer North America Lyme Disease Vaccine Ad Board, has provided expert testimony in malpractice cases, and has been issued the following patent: Elevated CCL19 after completion of therapy for acute Lyme disease identifies patients at risk for development of post-treatment Lyme disease who will benefit from further antibiotic therapy. The remaining authors declare that they have no competing interests.